Distribution of natural resistance to NS3 protease inhibitors in hepatitis C genotype 1a separated into clades 1 and 2 and in genotype 1b of HIV-infected patients

S. Bagaglio; Caterina Uberti Foppa; E. Messina; M. Merli; H. Hasson; A. Andolina; A. Galli; A. Lazzarin; Giulia Morsica

doi:10.1016/j.cmi.2015.12.007

Distribution of natural resistance to NS3 protease inhibitors in hepatitis C genotype 1a separated into clades 1 and 2 and in genotype 1b of HIV-infected patients

S. Bagaglio, Caterina Uberti Foppa, E. Messina, M. Merli, H. Hasson, A. Andolina, A. Galli, A. Lazzarin, Giulia Morsica

IRCCS Ospedale San Raffaele

Research output: Contribution to journal › Article

Abstract

Naturally occurring resistance-associated variants (RAVs) within the protease domain of hepatitis C virus (HCV) genotype (G) 1a separated into clades 1 and 2, and G1b were investigated in 59 HIV/HCV coinfected patients. RAVs were detected in 10/23 G1a/clade 1 and 1/19 G1b (p 0.0059). A similar frequency of RAVs was found when comparing G1a/clade 2 and G1b (p 0.1672). A cross-resistance to the macrocyclic compounds simeprevir and paritaprevir was detected in two G1a/clade 2 and 1 G1b sequences and none of G1a/clade 1 sequences. The simultaneous characterization of subtype and natural RAVs by population analysis of the NS3 domain by may add important information for anti-HCV treatment strategies including protease inhibitors.

Original language	English
Pages (from-to)	386.e1 - 386.e3
Journal	Clinical Microbiology and Infection
Volume	22
Issue number	4
DOIs	https://doi.org/10.1016/j.cmi.2015.12.007
Publication status	Published - Apr 1 2016

Fingerprint

Keywords

Clades 1 and 2
Genotype 1a
HCV-PI
HIV
Natural RAV
Q80K polymorphism

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Cite this

Bagaglio, S., Uberti Foppa, C., Messina, E., Merli, M., Hasson, H., Andolina, A., Galli, A., Lazzarin, A., & Morsica, G. (2016). Distribution of natural resistance to NS3 protease inhibitors in hepatitis C genotype 1a separated into clades 1 and 2 and in genotype 1b of HIV-infected patients. Clinical Microbiology and Infection, 22(4), 386.e1 - 386.e3. https://doi.org/10.1016/j.cmi.2015.12.007

Distribution of natural resistance to NS3 protease inhibitors in hepatitis C genotype 1a separated into clades 1 and 2 and in genotype 1b of HIV-infected patients. / Bagaglio, S.; Uberti Foppa, Caterina; Messina, E.; Merli, M.; Hasson, H.; Andolina, A.; Galli, A.; Lazzarin, A.; Morsica, Giulia.

In: Clinical Microbiology and Infection, Vol. 22, No. 4, 01.04.2016, p. 386.e1 - 386.e3.

Research output: Contribution to journal › Article

Bagaglio, S, Uberti Foppa, C, Messina, E, Merli, M, Hasson, H, Andolina, A, Galli, A, Lazzarin, A & Morsica, G 2016, 'Distribution of natural resistance to NS3 protease inhibitors in hepatitis C genotype 1a separated into clades 1 and 2 and in genotype 1b of HIV-infected patients', Clinical Microbiology and Infection, vol. 22, no. 4, pp. 386.e1 - 386.e3. https://doi.org/10.1016/j.cmi.2015.12.007

Bagaglio, S. ; Uberti Foppa, Caterina ; Messina, E. ; Merli, M. ; Hasson, H. ; Andolina, A. ; Galli, A. ; Lazzarin, A. ; Morsica, Giulia. / Distribution of natural resistance to NS3 protease inhibitors in hepatitis C genotype 1a separated into clades 1 and 2 and in genotype 1b of HIV-infected patients. In: Clinical Microbiology and Infection. 2016 ; Vol. 22, No. 4. pp. 386.e1 - 386.e3.

@article{bacc2482279d40db9835206c6492432f,

title = "Distribution of natural resistance to NS3 protease inhibitors in hepatitis C genotype 1a separated into clades 1 and 2 and in genotype 1b of HIV-infected patients",

abstract = "Naturally occurring resistance-associated variants (RAVs) within the protease domain of hepatitis C virus (HCV) genotype (G) 1a separated into clades 1 and 2, and G1b were investigated in 59 HIV/HCV coinfected patients. RAVs were detected in 10/23 G1a/clade 1 and 1/19 G1b (p 0.0059). A similar frequency of RAVs was found when comparing G1a/clade 2 and G1b (p 0.1672). A cross-resistance to the macrocyclic compounds simeprevir and paritaprevir was detected in two G1a/clade 2 and 1 G1b sequences and none of G1a/clade 1 sequences. The simultaneous characterization of subtype and natural RAVs by population analysis of the NS3 domain by may add important information for anti-HCV treatment strategies including protease inhibitors.",

keywords = "Clades 1 and 2, Genotype 1a, HCV-PI, HIV, Natural RAV, Q80K polymorphism",

author = "S. Bagaglio and {Uberti Foppa}, Caterina and E. Messina and M. Merli and H. Hasson and A. Andolina and A. Galli and A. Lazzarin and Giulia Morsica",

year = "2016",

month = apr

day = "1",

doi = "10.1016/j.cmi.2015.12.007",

language = "English",

volume = "22",

pages = "386.e1 -- 386.e3",

journal = "Clinical Microbiology and Infection",

issn = "1198-743X",

publisher = "Elsevier B.V.",

number = "4",

}

TY - JOUR

T1 - Distribution of natural resistance to NS3 protease inhibitors in hepatitis C genotype 1a separated into clades 1 and 2 and in genotype 1b of HIV-infected patients

AU - Bagaglio, S.

AU - Uberti Foppa, Caterina

AU - Messina, E.

AU - Merli, M.

AU - Hasson, H.

AU - Andolina, A.

AU - Galli, A.

AU - Lazzarin, A.

AU - Morsica, Giulia

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Naturally occurring resistance-associated variants (RAVs) within the protease domain of hepatitis C virus (HCV) genotype (G) 1a separated into clades 1 and 2, and G1b were investigated in 59 HIV/HCV coinfected patients. RAVs were detected in 10/23 G1a/clade 1 and 1/19 G1b (p 0.0059). A similar frequency of RAVs was found when comparing G1a/clade 2 and G1b (p 0.1672). A cross-resistance to the macrocyclic compounds simeprevir and paritaprevir was detected in two G1a/clade 2 and 1 G1b sequences and none of G1a/clade 1 sequences. The simultaneous characterization of subtype and natural RAVs by population analysis of the NS3 domain by may add important information for anti-HCV treatment strategies including protease inhibitors.

AB - Naturally occurring resistance-associated variants (RAVs) within the protease domain of hepatitis C virus (HCV) genotype (G) 1a separated into clades 1 and 2, and G1b were investigated in 59 HIV/HCV coinfected patients. RAVs were detected in 10/23 G1a/clade 1 and 1/19 G1b (p 0.0059). A similar frequency of RAVs was found when comparing G1a/clade 2 and G1b (p 0.1672). A cross-resistance to the macrocyclic compounds simeprevir and paritaprevir was detected in two G1a/clade 2 and 1 G1b sequences and none of G1a/clade 1 sequences. The simultaneous characterization of subtype and natural RAVs by population analysis of the NS3 domain by may add important information for anti-HCV treatment strategies including protease inhibitors.

KW - Clades 1 and 2

KW - Genotype 1a

KW - HCV-PI

KW - HIV

KW - Natural RAV

KW - Q80K polymorphism

UR - http://www.scopus.com/inward/record.url?scp=84960153962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960153962&partnerID=8YFLogxK

U2 - 10.1016/j.cmi.2015.12.007

DO - 10.1016/j.cmi.2015.12.007

M3 - Article

VL - 22

SP - 386.e1 - 386.e3

JO - Clinical Microbiology and Infection

JF - Clinical Microbiology and Infection

SN - 1198-743X

IS - 4

ER -

Access to Document

10.1016/j.cmi.2015.12.007